Skip to main content

CNS Pharmaceuticals, Inc.

corporate_fare Company Profile

CNS Pharmaceuticals, Inc.

CNSP·NASDAQ·Life Sciences·CIK 0001729427

CNS Pharmaceuticals, Inc. is a biotechnology company that develops innovative therapies for serious diseases in neurology and oncology. These therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending and include prevalent and difficult-to-treat diseases with significant unmet medical needs. The company aims to build a differentiated portfolio of assets with best-in-class potential. On January 1, 2026, Rami Levin, MBA, was appointed President & Chief Executive Officer. Following this, an independent life science focused advisory firm conducted a comprehensive data-driven analysis of the company's pipeline, development priorities, and long-term positioning. While this Strategic Analysis was underway, the company rebuilt its executive leadership team, appointing a new Chief Business Officer, Chief Financial Officer, Chief Medical Officer, and Chief Technology Officer effective March 2, 2026. This team was assembled to execute the findings and recommendations of the Strategic Analysis and develop a new corporate strategy. On March 11, 2026, CNS Pharmaceuticals announced a new corporate growth strategy focused on building a high-value pipeline in neurology and oncology. This strategy resulted from the comprehensive, data-driven strategic review, which included clinical probability-of-success modeling, competitive landscape assessments, regulatory pathway analyses, and risk-adjusted return evaluations.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for CNSP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for CNSP spans 10-Q, 8-K, 424B3, 4.

Recent high-impact activity:

  • CNS Pharmaceuticals Q3 2026: $10.0M Nine-Month Loss, $17.2M Cash, Material Weakness Persists
  • CNS Pharma Posts $2.6M Q2 Loss, $20M Cash After $22.5M Placement
  • CNS Pharma Posts Q2 Loss, Flags Material Weaknesses, and Outlines $22.5M Private Placement
  • CNS Pharmaceuticals Details Strategic Pivot and Fully Diluted Capital Structure in Investor Presentation
  • CNS Pharmaceuticals Registers 9.8M Shares for Resale, Enabling Massive Dilution from Recent Private Placement

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$15.85M
Diluted EPS
-$35.75
Op. Cash Flow
-$13.81M
Free Cash Flow
-$13.83M
Operating Income
-$15.99M
Cash & Equivalents
$7.2M
Debt / Equity
0.00×
Shares Outstanding
632.52K sh
Source: 10-K · filed 2026-04-30 · accession 0001683168-26-003374

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 1,638 shares in CNSP as of the October 30, 2026 settlement, a 26.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 22.2% of CNSP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,638 shares as of October 30, 2026
Change vs prior period▲ 26.0%
Days to cover1.00 at avg daily volume of 23,863
Daily short volume (FINRA facilities)22.2% of 180 shares on November 20, 2026
5-day average short volume25.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for CNSP, detected from its recent SEC filings · based on capital-structure filings through 2026-05-26.

Resale of 9.8 Million Shares Enabled · Massive Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$3.92
52-week range · as of 2026-11-16 $1.9 – $10.54
Market cap
$5.25M
Volume
668 (0.0× avg)
3-mo avg 14.2K
Live data · 2026-11-21 08:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CNSP - Latest Insights

CNSP
Nov 16, 2026, 7:30 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $3.92 info
Change: +$0.925 (+31%) info
Market Cap: $5.253M info
CNSP
Aug 12, 2026, 8:09 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.99
Real-time Price: $3.92 info
Change: -$1.07 (-22%) info
Market Cap: $5.253M info
CNSP
Aug 12, 2026, 7:56 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.99
Real-time Price: $3.92 info
Change: -$1.07 (-22%) info
Market Cap: $5.253M info
CNSP
Jul 02, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.68
Real-time Price: $3.92 info
Change: -$0.765 (-16%) info
Market Cap: $5.253M info
CNSP
May 26, 2026, 5:01 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $5.07
Real-time Price: $3.92 info
Change: -$1.16 (-23%) info
Market Cap: $5.253M info
CNSP
May 20, 2026, 9:03 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $4.77
Real-time Price: $3.92 info
Change: -$0.855 (-18%) info
Market Cap: $5.253M info
CNSP
May 19, 2026, 4:55 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $4.65
Real-time Price: $3.92 info
Change: -$0.735 (-16%) info
Market Cap: $5.253M info
CNSP
May 14, 2026, 8:00 AM EDT
Source: Access Newswire
Importance Score:
9
Price at Filing: $5.12
Real-time Price: $3.92 info
Change: -$1.21 (-24%) info
Market Cap: $5.253M info
CNSP
May 14, 2026, 7:55 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.12
Real-time Price: $3.92 info
Change: -$1.21 (-24%) info
Market Cap: $5.253M info
CNSP
May 04, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.90
Real-time Price: $3.92 info
Change: -$0.985 (-20%) info
Market Cap: $5.253M info
CNSP
Apr 30, 2026, 4:30 PM EDT
Filing Type: 10-K/A
Importance Score:
9
Price at Filing: $2.27
Real-time Price: $3.92 info
Change: +$1.65 (+72%) info
Market Cap: $5.253M info
CNSP
Mar 31, 2026, 4:35 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.39
Real-time Price: $3.92 info
Change: +$1.53 (+64%) info
Market Cap: $5.253M info
CNSP
Mar 31, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.40
Real-time Price: $3.92 info
Change: +$1.52 (+63%) info
Market Cap: $5.253M info
CNSP
Mar 11, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.26
Real-time Price: $3.92 info
Change: +$0.6596 (+20%) info
Market Cap: $5.253M info
CNSP
Mar 11, 2026, 8:35 AM EDT
Source: Acceswire
Importance Score:
8
Price at Filing: $3.36
Real-time Price: $3.92 info
Change: +$0.555 (+17%) info
Market Cap: $5.253M info
CNSP
Mar 02, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.00
Real-time Price: $3.92 info
Change: +$0.915 (+31%) info
Market Cap: $5.253M info
CNSP
Feb 17, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $3.92 info
Change: +$0.445 (+13%) info
Market Cap: $5.253M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets